Daiichi Sankyo : Announces the Sale of Its Nihonbashi Building in Japan

For Immediate Release

2019.04.25

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and COO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma,
Vice President, Corporate Communications Department
Telephone: [phone]
https://www.daiichisankyo.com

Daiichi Sankyo Announces the Sale of Its Nihonbashi Building in Japan

Tokyo, Japan (April 25, 2019) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has sold its wholly owned Nihonbashi Building located at Nihonbashi 3-chome, Chuo-ku, Tokyo, Japan.

As part of Daiichi Sankyo's efforts toward the realization of its Vision for 2025 of being a 'Global Pharma Innovator with competitive advantage in oncology', the company is prioritizing resource allocation to the oncology therapeutic area. 'Reinforcing profit generation capability' has been determined as a strategy for achieving this Vision, and the Nihonbashi Building was sold based on a policy of producing cash from non-core assets. Following the sale, Daiichi Sankyo will lease the building back from buyer and continue its current business activities there.

A profit of approximately 10.6 billion (before tax) will be recorded for the first quarter of fiscal 2019 on the sale of the Nihonbashi Building. However, at the request of the buyer, Daiichi Sankyo is not disclosing the buyer's name nor the amount of the sale.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a 'Global Pharma Innovator with Competitive Advantage in Oncology,' Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.